Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: AD Hypotheses: Hypothesis Factory
HYPOTHESIS FACTORY


Posted 12 August 2005

Cholesterol and AD
By Chris Masterjohn

The product of the ε4 allele of apolipoprotein E (ApoE4) is less efficient at delivering cholesterol to cells. This appears to be contradicted by in vitro evidence that it is slightly more efficient at internalizing cholesterol than the product of the ε3 allele (ApoE3) when incubated in β-VLDL, but it is supported by observations that ApoE4 has a preferential affinity for low-cholesterol lipoproteins.

Dr. Iwo Bohr suggested in his recent hypothesis (1) that ApoE4 is less efficient at delivering cholesterol to cells, citing Lane and Farlow (2), extrapolating from their discussion of the deficiency of free fatty acid delivery resulting from the suppression of lipoprotein lipase, which is a result of the preferential affinity of ApoE4 for high-triglyceride lipoproteins, displacing ApoC-II. Dr. Bohr also notes higher cholesterol levels associated with ApoE4, which could be indicative of deficient delivery to cells. However, this suggestion seemed to be contradicted by in vitro evidence from Zheng-Shong et al., who showed in 1998 that ApoE4 was slightly more efficient than ApoE3, both incubated in β-VLDL, at internalizing cholesterol in neuronal cell culture (3). The observation of Zheng-Shong et al. has diminished relevance to in vivo dynamics because it utilized only β-VLDL rather than a full spectrum of lipoproteins.

The discussion of Lane and Farlow referring to ApoE4's preferential affinity for high-triglyceride lipoproteins relative to ApoE3 and ApoE2 should be supplemented with the corollary of this observation: ApoE4 demonstrates a preferential affinity for low-cholesterol lipoproteins. According to Figure 2.10 in Dr. Mary G. Enig's Know Your Fats (4), there is an inverse relationship between percentage cholesterol and percentage triglyceride in lipoproteins, excluding HDL. Triglycerides range from 89 percent of chylomicrons to 7 percent of IDLs, while cholesterol ranges from 4 percent of chylomicrons to 44 percent of IDLs. Thus, the preferential affinity of ApoE4 for high-triglyceride lipoproteins, namely chylomicrons and VLDL, should translate as a preferential affinity of ApoE4 for low-cholesterol lipoproteins.

It is my hypothesis that ApoE4 results in less efficient delivery of cholesterol to neuronal cells primarily through its preferential affinity for high-triglyceride, low-cholesterol lipoproteins, relative to ApoE3 and ApoE2. This supports Dr. Bohr's suggestion that ApoE4's causal contribution to Alzheimer disease is related to its inability to efficiently deliver cholesterol to cells, which is necessary for proper cholinergic function.

I will be discussing this observation further in an upcoming article on my website Cholesterol-And-Health.com, which will be referred to as Part II of Myth: Cholesterol Causes Alzheimer's Disease.

References:
1. Bohr IJ. Does cholesterol act as a protector of cholinergic projections in Alzheimer's disease? Lipids Health Dis. 2005 Jun 10;4:13. Abstract

2. Lane RM, Farlow MR. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res. 2005 May;46(5):949-68. Epub 2005 Feb 16. Abstract

3. Ji ZS, Pitas RE, Mahley RW. Differential Cellular Accumulation/Retention of Apolipoprotein E Mediated by Cell Surface Heparan Sulfate Proteoglycans. The Journal of Biological Chemistry. 1998 May 29;273(22):13452-13460. Abstract

4. Enig, Mary G., PhD, Know Your Fats: The Complete Primer for Understanding the Nutrition of Fats, Oils, and Cholesterol, Silver Spring: Bethseda Press, 2000, p70F.

 

RELATED LINKS
See related ARF Live Discussion: "Cholesterol and Alzheimer's--Charging Fast but Still at a Distance From Solid Answers." Current Hypotheses: Brain Cholesterol Pathology

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad